BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 17504870)

  • 21. Findings on 18F-FDG PET scans after neoadjuvant chemoradiation provides prognostic stratification in patients with locally advanced rectal carcinoma subsequently treated by radical surgery.
    Kalff V; Duong C; Drummond EG; Matthews JP; Hicks RJ
    J Nucl Med; 2006 Jan; 47(1):14-22. PubMed ID: 16391182
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Decreased 18F-FDG uptake 1 day after initiation of chemotherapy for malignant lymphomas.
    Yamane T; Daimaru O; Ito S; Yoshiya K; Nagata T; Ito S; Uchida H
    J Nucl Med; 2004 Nov; 45(11):1838-42. PubMed ID: 15534052
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tumor metabolic rates in sarcoma using FDG PET.
    Eary JF; Mankoff DA
    J Nucl Med; 1998 Feb; 39(2):250-4. PubMed ID: 9476930
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effects of estrogen, progesterone, and C-erbB-2 receptor states on 18F-FDG uptake of primary breast cancer lesions.
    Mavi A; Cermik TF; Urhan M; Puskulcu H; Basu S; Yu JQ; Zhuang H; Czerniecki B; Alavi A
    J Nucl Med; 2007 Aug; 48(8):1266-72. PubMed ID: 17631558
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Simplified kinetic analysis of tumor 18F-FDG uptake: a dynamic approach.
    Sundaram SK; Freedman NM; Carrasquillo JA; Carson JM; Whatley M; Libutti SK; Sellers D; Bacharach SL
    J Nucl Med; 2004 Aug; 45(8):1328-33. PubMed ID: 15299057
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of SUV and Patlak slope for monitoring of cancer therapy using serial PET scans.
    Freedman NM; Sundaram SK; Kurdziel K; Carrasquillo JA; Whatley M; Carson JM; Sellers D; Libutti SK; Yang JC; Bacharach SL
    Eur J Nucl Med Mol Imaging; 2003 Jan; 30(1):46-53. PubMed ID: 12483409
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multimodal prediction of neoadjuvant treatment outcome by serial FDG PET and MRI in women with locally advanced breast cancer.
    Kazerouni AS; Peterson LM; Jenkins I; Novakova-Jiresova A; Linden HM; Gralow JR; Hockenbery DM; Mankoff DA; Porter PL; Partridge SC; Specht JM
    Breast Cancer Res; 2023 Nov; 25(1):138. PubMed ID: 37946201
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Monitoring primary systemic therapy of large and locally advanced breast cancer by using sequential positron emission tomography imaging with [18F]fluorodeoxyglucose.
    Schwarz-Dose J; Untch M; Tiling R; Sassen S; Mahner S; Kahlert S; Harbeck N; Lebeau A; Brenner W; Schwaiger M; Jaenicke F; Avril N
    J Clin Oncol; 2009 Feb; 27(4):535-41. PubMed ID: 19075273
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Spatial and temporal heterogeneity of regional myocardial uptake in patients without heart disease under fasting conditions on repeated whole-body 18F-FDG PET/CT.
    Inglese E; Leva L; Matheoud R; Sacchetti G; Secco C; Gandolfo P; Brambilla M; Sambuceti G
    J Nucl Med; 2007 Oct; 48(10):1662-9. PubMed ID: 17873124
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glycolytic activity with 18F-FDG PET/CT predicts final neoadjuvant chemotherapy response in breast cancer.
    García Vicente AM; Cruz Mora MÁ; León Martín AA; Muñoz Sánchez Mdel M; Relea Calatayud F; Van Gómez López O; Espinosa Aunión R; Gonzalez Ageitos A; Soriano Castrejón A
    Tumour Biol; 2014 Nov; 35(11):11613-20. PubMed ID: 25139100
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Correcting tumour SUV for enhanced bone marrow uptake: retrospective 18F-FDG PET/CT studies.
    Teo BK; Badiee S; Hadi M; Lam T; Johnson L; Seo Y; Bacharach SL; Hasegawa BH; Franc BL
    Nucl Med Commun; 2008 Apr; 29(4):359-66. PubMed ID: 18317301
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serial 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP).
    Specht JM; Tam SL; Kurland BF; Gralow JR; Livingston RB; Linden HM; Ellis GK; Schubert EK; Dunnwald LK; Mankoff DA
    Breast Cancer Res Treat; 2007 Sep; 105(1):87-94. PubMed ID: 17268819
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of colony-stimulating factor and conventional- or high-dose chemotherapy on FDG uptake in bone marrow.
    Kazama T; Swanston N; Podoloff DA; Macapinlac HA
    Eur J Nucl Med Mol Imaging; 2005 Dec; 32(12):1406-11. PubMed ID: 16133379
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Changes in 18F-FDG uptake within minutes after chemotherapy in a rabbit VX2 tumor model.
    Song SL; Liu JJ; Huang G; Wang ZH; Song YY; Sun XG; Chen T
    J Nucl Med; 2008 Feb; 49(2):303-9. PubMed ID: 18199614
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of breast tumor blood flow with dynamic first-pass 18F-FDG PET/CT: comparison with angiogenesis markers and prognostic factors.
    Cochet A; Pigeonnat S; Khoury B; Vrigneaud JM; Touzery C; Berriolo-Riedinger A; Dygai-Cochet I; Toubeau M; Humbert O; Coudert B; Fumoleau P; Arnould L; Brunotte F
    J Nucl Med; 2012 Apr; 53(4):512-20. PubMed ID: 22343501
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preoperative FDG-PET for axillary metastases in patients with breast cancer.
    Chung A; Liou D; Karlan S; Waxman A; Fujimoto K; Hagiike M; Phillips EH
    Arch Surg; 2006 Aug; 141(8):783-8; discussion 788-9. PubMed ID: 16924086
    [TBL] [Abstract][Full Text] [Related]  

  • 37. TBCRC 008: early change in 18F-FDG uptake on PET predicts response to preoperative systemic therapy in human epidermal growth factor receptor 2-negative primary operable breast cancer.
    Connolly RM; Leal JP; Goetz MP; Zhang Z; Zhou XC; Jacobs LK; Mhlanga J; O JH; Carpenter J; Storniolo AM; Watkins S; Fetting JH; Miller RS; Sideras K; Jeter SC; Walsh B; Powers P; Zorzi J; Boughey JC; Davidson NE; Carey LA; Wolff AC; Khouri N; Gabrielson E; Wahl RL; Stearns V
    J Nucl Med; 2015 Jan; 56(1):31-7. PubMed ID: 25476537
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Does the pretreatment tumor sampling location correspond with metabolic activity on 18F-FDG PET/CT in breast cancer patients scheduled for neoadjuvant chemotherapy?
    Koolen BB; Elshof LE; Loo CE; Wesseling J; Vrancken Peeters MJ; Vogel WV; Rutgers EJ; Valdés Olmos RA
    Eur J Radiol; 2013 Dec; 82(12):2353-8. PubMed ID: 23998705
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Positron emission tomography in non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglucose.
    Römer W; Hanauske AR; Ziegler S; Thödtmann R; Weber W; Fuchs C; Enne W; Herz M; Nerl C; Garbrecht M; Schwaiger M
    Blood; 1998 Jun; 91(12):4464-71. PubMed ID: 9616140
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Value of fused 18F-FDG PET/CT images in predicting efficacy of neoadjuvant chemotherapy on breast cancer].
    Li D; Chen JH; Wang J; Ling R; Yao Q; Wang L
    Ai Zheng; 2007 Aug; 26(8):900-4. PubMed ID: 17697556
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.